Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer

Author:

Cevik Mehtap1,Namal Esat2,Sener Nur Dinc2,Koksal Ulkuhan Iner3,Cagatay Penbe4,Deliorman Gokce5,Ciftci Cavlan6,Karaalp Atila7ORCID,Susleyici Belgin1ORCID

Affiliation:

1. Department of Molecular Biology, Marmara University Faculty of Arts and Science, Istanbul, 34722, Turkey

2. Department of Medical Oncology, Demiroglu Bilim University Faculty of Medicine, Istanbul, 34394, Turkey

3. Istanbul Bagcilar Training & Research Hospital, Istanbul, 34200, Turkey

4. Department of Medical Services & Technics, Vocational School of Health Service, Istanbul University – Cerrahpasa, Istanbul, 34320, Turkey

5. Department of Software Engineering, Beykoz University Faculty of Engineering & Architecture, Istanbul, 34810, Turkey

6. Department of Cardiology, Demiroglu Bilim University Faculty of Medicine, Istanbul, 34394, Turkey

7. Department of Medical Pharmacology, Marmara University Faculty of Medicine, Istanbul, 34854, Turkey

Abstract

Aim: To investigate the association of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil (5-FU) related toxicities and patient survival. Materials & methods: A total of 103 colorectal cancer patients prescribed 5-FU were included in the study. Genotyping was conducted for several DPYD, MTHFR and TYMS polymorphisms using a microarray analyzer. Results: DPYD 496A>G polymorphism was found to be significantly associated with 5-FU related grade 0–2, but not severe toxicities (p = 0.02). Furthermore, patients with DPYD 85TC and CC genotypes had longer progression and overall survival times compared to TT genotypes in our study group (log rank = 6.60; p = 0.01 and log rank = 4.40; p = 0.04, respectively). Conclusion: According to our results, DPYD 496AG and GG genotypes might be protective against severe adverse events compared to the AA genotype. Another DPYD polymorphism, 85T>C, may be useful in colorectal cancer prognosis. Further studies for both polymorphisms should be conducted in larger populations to achieve accurate results.

Funder

Marmara Üniversitesi

Publisher

Future Medicine Ltd

Subject

Pharmacology,Molecular Medicine,General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3